Kangchen Pharmaceutical announced that KC1086, a Class 1 innovative drug independently developed by the company, is intended to be used to treat advanced recurrent or metastatic solid tumors. The company recently received a clinical trial notice approved and issued by the State Drug Administration, agreeing to conduct clinical research on HR+/HER2- locally advanced or metastatic breast cancer; the company plans to conduct phase II clinical studies of this joint program.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.